LUSID Pty Ltd
Company Profile:
• Executive level pharmaceutical manufacturing and operations management experience with FH Faulding
• Management of publicly-listed company, LBT Innovations Limited (LBT)
• Co-founded Adelaide-based, medical technology innovation company, LBT Innovations Limited
• Listed LBT Innovations on ASX (ASX Code: LBT) 2007
• Capital raising: raised approx. $60 million cash to fund LBT: 74% generated through operating cash flow, 26% via equity
• Significant experience and track record in product development and commercialisation for the healthcare industry, converting technology to product with market focus
• Intellectual property strategy – developed portfolio of over 16 patent families and design patents for LBT
• Regulatory strategy – 510(k) de novo submission to US FDA 2015
• Awarded AusIndustry Commercial Ready Grant $2.8 million (2007)
• Developed and commercialized breakthrough PREVI Isola robotic instrumentation for automation of microbiology testing launched 2009 with global licence partner French diagnostics company bioMérieux
• Developed and commercialized breakthrough AI technology for automation of imaging, analysis and interpretation of microbiology culture plates (APAS) 2010-2016
• Formed joint venture company Clever Culture Systems AG, Switzerland to commercialise APAS technology developed by LBT Innovations 2013
• Awarded ARC Linkage Grant $510,000 in collaboration with ACVT (Australian Centre for Visual Technologies), University of Adelaide 2014
• Awarded $250,000 grant from the South Australian Government’s bioscience agency, BioSA, for the early stage development of LBT Innovations’ pioneering wound management technology Woundvue 2014
